Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group, has made a significant advancement in medical science by demonstrating the ability to deliver its proprietary Chimeric Bait Receptor (CBR) into the brain via programmed microglial cells. This innovative approach opens new doors for the potential treatment of brain cancers and certain neurodegenerative diseases, tackling the […]
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group, has made a significant stride in the realm of biotechnology with its recent in vivo demonstration of the Chimeric Bait Receptor (CBR) delivery via intranasal route using messenger RNA (mRNA). This innovative approach marks a potential game-changer for the treatment of airborne viral infections, showcasing a […]
Hemogenyx Pharmaceuticals plc, a London-based biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) to proceed with its Phase I clinical study of HEMO-CAR-T, marking a significant milestone in the treatment of acute myeloid leukemia (AML). This development follows the FDA’s decision to lift the clinical hold on the Investigational New […]